These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34600560)

  • 1. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.
    Wang S; Zhou X; Zeng Z; Sui M; Chen L; Feng C; Huang C; Yang Q; Ji M; Hou P
    J Nanobiotechnology; 2021 Oct; 19(1):302. PubMed ID: 34600560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer.
    Wang Z; Zhu M; Dong R; Cao D; Li Y; Chen Z; Cai J; Zuo X
    J Nanobiotechnology; 2023 Nov; 21(1):440. PubMed ID: 37993847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis.
    Gong Y; Zhou T; Ma R; Yang J; Zhao Y; Pan M; Huang Z; Wen H; Jiang H; Wang J
    BMC Infect Dis; 2024 Aug; 24(1):778. PubMed ID: 39097707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy of Tumor Microenvironment Remodeling and Autophagy Inhibition to Sensitize Radiation for Bladder Cancer Treatment.
    Lin T; Zhang Q; Yuan A; Wang B; Zhang F; Ding Y; Cao W; Chen W; Guo H
    Theranostics; 2020; 10(17):7683-7696. PubMed ID: 32685013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing the chemotherapy effect of Apatinib on gastric cancer by co-treating with salidroside to reprogram the tumor hypoxia micro-environment and induce cell apoptosis.
    Zhang Z; Yang W; Ma F; Ma Q; Zhang B; Zhang Y; Liu Y; Liu H; Hua Y
    Drug Deliv; 2020 Dec; 27(1):691-702. PubMed ID: 32397840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-delivery photodynamic-hypoxia alleviating nanomedicine synergizes with anti-PD-L1 for cancer immunotherapy.
    Feng X; Chen Z; Liu Z; Fu X; Song H; Zhang Q
    Int J Pharm; 2023 May; 639():122970. PubMed ID: 37084832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodegradable Silk Fibroin Nanocarriers to Modulate Hypoxia Tumor Microenvironment Favoring Enhanced Chemotherapy.
    Bin L; Yang Y; Wang F; Wang R; Fei H; Duan S; Huang L; Liao N; Zhao S; Ma X
    Front Bioeng Biotechnol; 2022; 10():960501. PubMed ID: 35935500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defeating Melanoma Through a Nano-Enabled Revision of Hypoxic and Immunosuppressive Tumor Microenvironment.
    Yang W; Pan X; Zhang P; Yang X; Guan H; Dou H; Lu Q
    Int J Nanomedicine; 2023; 18():3711-3725. PubMed ID: 37435153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.
    Chen A; Yu Z; Ma N; Lu X; Zhang Y; Xu W; Wang Y; Xie J; Qin Y; Mo G; Wu S; Hou J; Zhu W
    Cancer Immunol Immunother; 2024 Feb; 73(3):49. PubMed ID: 38349553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.
    Cheng WJ; Chen LC; Ho HO; Lin HL; Sheu MT
    Int J Nanomedicine; 2018; 13():7079-7094. PubMed ID: 30464460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.
    Ashton TM; Fokas E; Kunz-Schughart LA; Folkes LK; Anbalagan S; Huether M; Kelly CJ; Pirovano G; Buffa FM; Hammond EM; Stratford M; Muschel RJ; Higgins GS; McKenna WG
    Nat Commun; 2016 Jul; 7():12308. PubMed ID: 27453292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone.
    Calvo J; Lavandera JL; Agüeros M; Irache JM
    Biomed Microdevices; 2011 Dec; 13(6):1015-25. PubMed ID: 21773725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
    Bao X; Shen N; Lou Y; Yu H; Wang Y; Liu L; Tang Z; Chen X
    Theranostics; 2021; 11(12):5955-5969. PubMed ID: 33897892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma.
    Zhang N; Song J; Liu Y; Liu M; Zhang L; Sheng D; Deng L; Yi H; Wu M; Zheng Y; Wang Z; Yang Z
    J Control Release; 2019 Jul; 306():15-28. PubMed ID: 31132380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O
    Lin T; Zhao X; Zhao S; Yu H; Cao W; Chen W; Wei H; Guo H
    Theranostics; 2018; 8(4):990-1004. PubMed ID: 29463995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.
    Zou MZ; Liu WL; Li CX; Zheng DW; Zeng JY; Gao F; Ye JJ; Zhang XZ
    Small; 2018 Jul; 14(28):e1801120. PubMed ID: 29882235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
    Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
    Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
    J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi HG; Park ES; Youn YS
    Int J Pharm; 2016 Jan; 497(1-2):268-76. PubMed ID: 26657273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.